Study Summary
This single-arm,multicenter Phase 2 trial will treat the patients who have recurrent or refractory acute non T lymphocyte leukemia with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to tumour cells that express the EPCAM protein on the cell surface.The study will determine if these modified T cells help the body's immune system eliminate tumour cells.The trial will also study the safety of treatment with CAR-T,how long CAR-T cells stay in the patient's body and the impact of this treatment on survival.
Want to learn more about this trial?
Request More InfoInterventions
CD19-targeted CAR-T cellsBIOLOGICAL
This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Second Hospital of Anhui Medical University | Hefei | Anhui | China |
| No. 454 Hospital of People'S Liberation Army | Nanjing | Jiangsu | China |